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Standfirst 
Clinical prediction models estimate the risk of existing disease or future outcome for an individual, 
conditional on their values of multiple predictors such as age, sex and biomarkers. In this article, 
Bonnett and colleagues provide a guide to presenting clinical prediction models so that they can be 
implemented in practice, if appropriate. They describe how to create four presentation formats, and 
discuss the advantages and disadvantages of each. A key message is the need for stakeholder 
engagement to determine the best presentation option in relation to the clinical context of use and the 
intended user. 
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Introduction 
Clinical prediction models estimate the risk of existing disease (diagnostic prediction model) or future 
outcome (prognostic prediction model) for an individual, conditional on their values of multiple 
predictors (prognostic or risk factors) such as age, sex and biomarkers.1 A large number of prediction 
models are published in the medical literature each year,2 and most are developed using a regression 
framework such as logistic and Cox regression, as outlined in Box 1. Prediction models are also known 
as risk scores, prognostic indices, or prognostic scores. Examples include the Framingham risk score 
which predicts 10-year risk of coronary heart disease3 and the APACHE scores for mortality after 
intensive care admission.4 5  
The transparent reporting of a multivariable prediction model for individual prognosis or diagnosis 
(TRIPOD) statement provides guidance on key information for authors to report when developing or 
validating prediction models.6 7 However, whilst the TRIPOD Statement highlights the importance of 
model presentation, there is relatively little information or practical guidance on how to actually 
present a prediction model for use after development, for example to aid implementation in clinical 
settings, if appropriate. A key resource is the excellent book chapter (chapter 18) by Steyerberg.8  
When choosing the format to present a prediction model, researchers should carefully consider the 
intended user, setting and moment of use. It is helpful to ask: “who will be accessing the model in this 
format, and when and in what setting will they use it?”, and to then tailor the presentation format 
accordingly. Fundamentally, the full model equation should always be presented in the journal 
publication6 7; this is essential to enable an independent external validation. However, additional 
presentation formats may be required, perhaps outside of the journal article, to enable healthcare 
professionals to use the model in a particular clinical setting (e.g. where their access to computers or 
mobile devices is limited). Similarly, the format may need tailoring for a lay person using the model at 
home (e.g. an asthma patient deciding on appropriate management of their condition using Asthma 
UK’s asthma attack risk checker9), to improve shared-decision making.10 User groups can help guide 
the best presentation choices in each situation, including healthcare professionals, patients and the 
general public. Patient-public involvement groups and focus groups are useful arenas for this, which 
aligns with the need for public and participant information and engagement (PPIE) within health 
research.  
Therefore, alongside the full model equation, a range of presentation formats may be required that 
differ according to the medium by which they are presented (paper versus electronic), the setting in 
which the models are to be applied (e.g. clinic, bedside, or at home), the level of detail wanted in the 
predictions (e.g. approximate or rounded risk estimates, or exact risk estimates), and user-friendliness 
(simple to complex formats).8 In this paper, we summarise four key ways of presenting clinical 
prediction models that may aid their use in clinical practice, if appropriate. We outline how to create 
each format, and describe their advantages and disadvantages in relation to the clinical context of 
use, and the intended user. An overview of the different presentation formats is shown in Table 1. 
We emphasise that our article is not about how to develop or validate a prediction model,8 11 or indeed 
how to decide if it is fit for clinical use.1 12 Rather, we assume a model has been developed and has 
been deemed potentially useful for clinical practice, and so the researcher needs to consider how to 
present the model to aid implementation. For this purpose we use the model shown in Box 2, which 
is for illustrative purposes only, predicting mortality risk over time in those diagnosed with a primary 
biliary cirrhosis. This survival model is used throughout the article, but the presentation formats 
described also apply to other risk prediction models developed using regression, such as those derived 
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using logistic regression, and many are relevant for prediction of a continuous outcome (e.g. using 
linear regression).  
Table 1: Examples of formats for presenting clinical prediction models to enable outcome risks to be calculated for new 
individuals; these should be considered after also presenting the full model equation  
Presentation 
Format 
Explanation Advantages Disadvantages Example 
Points score 
system 
Comprises of two tables – 
one which enables a total 
points score to be 
calculated based on 
predictor values, and the 
other which provides an 
estimate of risk based on 
the total points score 
 Easy to understand 
 Predictions are 
approximate 
 Need predictions at 
each time point of 
interest for survival 
outcomes 
 Continuous predictors 
must be categorised 
Renal 
artery 
stenosis13 
Graphical score 
chart 
Graphical representation 
of a highly-simplified 
points score system 
 Easy to understand 
 Can only accommodate 
a limited number of 
predictors 
 Need one per time 
point of interest for 
survival outcomes 
 Prediction to a range of 
event probabilities and 
thus predictions are 
approximate 
 Continuous predictors 
must be categorised 
Traumatic 
bleeding14 
Nomogram 
Graphical presentation of 
a prediction model – 
points are assigned based 
on predictor values which 
are then summed and 
translated to an estimate 
of risk of outcome 
 Can easily be applied 
away from a computer 
(e.g. community based 
medicine) 
 Can initially be difficult 
to understand 
 May be inaccurate 
depending on the size 
and resolution of the 
published nomogram 
Prostate 
cancer15 
 
Coronary 
heart 
disease16 
Websites and 
applications 
Interactive graphical user 
interface which provides 
risk estimates from the 
underlying (often hidden) 
prediction model after a 
user inputs predictor 
values 
 Visually appealing to 
intended users 
 Can automate complex 
modelling methods in 
the background 
 Full equation is retained 
(albeit in the 
background) 
 Can quickly produce risk 
predictions at multiple 
time-points for survival 
outcomes 
 Can automate the 
extraction of predictor 
values (e.g. from e-
health records, or from 
available hardware such 
as GPS coordinates, 
calendar time, blood 
pressure etc.) 
 Easy access may lead to 
over-use or access by 
individuals who may not 
be the target population 
 Can be created by 
anyone so no guarantee 
model has been 
developed well 
 Often difficult to know 
how the model 
equation has been 
translated to the 
graphical tool 
 Often unclear whether 
it is of relevance or 
indeed has been 
validated in relevant 
population 
 Possible privacy and 
data storage issues 
 Model may change over 
time and by location 
without changes being 
tracked 
Breast 
cancer10 
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Box 1: Typical format of prediction models developed using regression 
to enable risk predictions in new individuals (Text adapted from Riley et al.17)  
Short-term clinical prediction models or diagnostic models 
If the outcome can take one of only two options (e.g. death, or presence of the disease) and is known 
for all patients at a particular time-point, a prediction model can be developed using logistic 
regression. This has the following form: 
𝑙𝑛 (
𝑝
1 − 𝑝
) = 𝛼 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ 
Here p is the probability of having the outcome and 𝑙𝑛 (
𝑝
1−𝑝
) is the log odds of the outcome. 𝛼 is the 
intercept term and the baseline log-odds where ‘baseline’ refers to individuals whose X values are all 
zero. If all 𝑋 predictors are centred at the mean, 𝛼 is the log-odds for a person with average 𝑋 values. 
The 𝑋 terms denote values of included predictors so that 𝑋1 might represent the age of the patient in 
years, 𝑋2 could represent gender and be 1 for males and 0 for females etc. The 𝛽 terms denote the 
change in log odds (otherwise known as the log odds ratio) for each 1-unit increase in the 
corresponding predictor. For example, 𝛽1 might be the increase in the log odds for each one year 
increase in age, and 𝛽2 might be the increase in the log odds for a male compared to a female. Risk 
(outcome probability) predictions, ?̂?, for a new individual can be estimated by inputting their predictor 
values into the equation and then transforming back to the probability scale: 
?̂? =
𝑒𝑥𝑝(𝛼 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ )
1 + 𝑒𝑥𝑝(𝛼 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ )
 
Clinical prediction models over time 
If risks are predicted over time, or at a time-point when some individuals in the dataset have previously 
dropped out or been lost to follow up (i.e. censored), a prediction model can be developing using a 
survival model such as a Cox model or a parametric survival model. This has the following form: 
ℎ(𝑡) = ℎ0(𝑡) 𝑒𝑥𝑝(𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ ) 
Here ℎ(𝑡) is the hazard rate of the outcome at time t and ℎ0(𝑡) is the baseline hazard rate.  The 𝑋 
terms denote values of included predictors, and each 𝛽 denotes the change in log hazard rate 
(otherwise known as the log hazard ratio) for each 1-unit increase in the corresponding predictor. 
‘Baseline’ refers to individuals whose X values are all zero, or if all predictors are centred at the mean, 
the underlying hazard rate for a person with average 𝑋 values.  
Predictions of not having the outcome at time t (‘survival’ probability) for a new individual can be 
obtained by inputting their predictor values into the equation and then transforming back to the 
probability scale, 
?̂?(𝑡) =  𝑆0(𝑡)
𝑒𝑥𝑝(𝛽1𝑋1+𝛽2𝑋2+𝛽3𝑋3+⋯ ) 
where 𝑆0(𝑡) is the baseline survival probability at time t. Conversely, risk predictions (outcome 
probability) for having the outcome at time t for a new individual can be calculated as:  
1 − ?̂?(𝑡) =  1 − 𝑆0(𝑡)
𝑒𝑥𝑝(𝛽1𝑋1+𝛽2𝑋2+𝛽3𝑋3+⋯ ) 
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Box 2: Primary Biliary Cirrhosis – example dataset & prediction model 
Clinical Context 
This data is from an international trial on the therapeutic effect of the immunosuppressant drug 
azathioprine in primary biliary cirrhosis (also known as primary biliary cholangitis) of the liver, and is 
publically available.18 19 Primary biliary cirrhosis is an autoimmune condition which can get worse over 
time and without treatment may lead to liver failure. A total of 248 primary biliary cirrhosis patients 
met eligibility criteria for the randomised placebo controlled trial of whom 127 received the 
intervention and 121 the placebo. There were 57 (45%) deaths in the treatment group and 62 (51%) 
in the control group. Risk prediction is important to guide patient counselling and potentially inform 
treatment choice.  
Predictors 
Predictors of interest were age (years), presence of cirrhosis (yes/no), albumin (g/dl), presence of 
central cholestasis (yes/no), and placebo treatment (rather than azathioprine, yes/no). Characteristics 
of these predictors, including the ranges of the continuous predictors, can be seen in Table 2. 
Treatment was explicitly modelled.20 
Table 2: Patient characteristics for the primary biliary cirrhosis running example 
Continuous Predictor Range Mean (SD) Binary Predictor Coding N (%) 
Age (years) 25.0-78.0 54.8 (10.6) Cirrhosis 
No: 0 
Yes: 1 
148 (71.5) 
59 (28.5) 
Albumin (g/dl) 20.0-56.5 34.4 (5.9) Central cholestasis 
No: 0 
Yes: 1 
170 (82.1) 
37 (17.9) 
   Treatment 
Azathioprine: 0 
Placebo: 1 
109 (52.7) 
98 (47.3) 
Methods to Develop the Model 
A Cox proportional hazards regression model was fit to estimate probability of death from primary 
biliary cirrhosis with all predictor values centred at the mean predictor value in the study. As this was 
only an illustrative example, no adjustment for potential overfitting was made. 
Final Model Equation 
The estimated linear predictor (𝐿𝑃) for this model is the linear combination of predictors and their 
associated regression coefficients. I.e. for individual 𝑖,  
𝐿𝑃𝑖 = (0.02 × (𝐴𝑔𝑒 − 54.8)) + (1.06 × (𝐶𝑖𝑟𝑟ℎ𝑜𝑠𝑖𝑠 − 0.285)) + (−0.06 × (𝐴𝑙𝑏𝑢𝑚𝑖𝑛 − 34.4)) +
(1.59 × (𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑎𝑠𝑖𝑠 − 0.179)) + (0.31 × 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡). 
The model for probability of death from primary biliary cirrhosis is shown below. Estimates of baseline 
survival at one (𝑆0(1)) and three years (𝑆0(3)) are also provided, based on a Nelson-Aalen type 
estimator. Note that time of predictions is made relevant by clinical and patient stakeholders. 
1 − 𝑆(𝑡) = 1 − 𝑆0(𝑡)
exp{𝐿𝑃𝑖} 
𝑆0(1) = 0.930; 𝑆0(3) = 0.759 
As predictor values are centered, the baseline 𝑆0(𝑡) in this equation relates to the survival probability 
over time for an “average” treated individual whose predictor values equal the mean predictor values 
in the study. As the prediction equation is derived from randomised controlled trial data the treatment 
effect can be assessed. This is in contrast to the more usual case where prediction equations are 
derived from cohort studies. 
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Presentation using a points score system 
Description 
Within points score systems, points are assigned based on the predictor values for a particular 
individual. The total points score is then mapped to a corresponding risk of event, or survival 
probability.21 The intended users for points score systems are healthcare professionals and patients. 
They can be presented on a screen (e.g. monitor, iPad) as part of a consultation, printed off as a take-
home sheet for patients, or used on the wards as a reference guide.  
How to derive a points score system 
To produce a points score system, a prediction model is first developed (e.g., using logistic or Cox 
regression; see Boxes 1 and 2), and the regression coefficients of included predictors are then assigned 
integer scores which can be negative or positive. Unfortunately, any continuous predictors need to be 
categorised to facilitate this, sacrificing some predictive accuracy. Categories do not need to be of 
equal size and by having unequal categories nonlinearity can be more appropriately handled. A 
summary of the steps to develop a points score system are as follows: 
1. Organise the continuous predictors into categories and determine the mid-point for each 
category. 
2. Choose a reference category for each predictor (continuous, binary and categorical). 
3. For continuous variables, determine how far each category is from the reference category, 
and then multiply each difference by the regression coefficient for that predictor to determine 
the difference in ‘regression units’. For binary and categorical variables, the ‘regression unit’ 
is just the regression coefficient for that predictor. 
4. Define the number of regression units that will correspond to one point in the points scoring 
system. This is usually based on clinician preference. 
5. Determine the points (rounded to the nearest integer) associated with each of the categories 
of the predictors. 
6. Determine the minimum and maximum possible points totals. 
7. Calculate the risk estimate for each points total across the range, by using the original model 
with the points scores (rounded) to get the predicted probabilities. This is essentially a new 
risk prediction model that is an approximation of the full model. 
Note that sometimes scores are derived based on hazard ratios or odds ratios rather than the 
corresponding regression coefficients. This approach is mathematically inappropriate as Cox (or 
logistic) regression models assume additivity of the log hazard (or log odds) ratios.22 
Alongside the point score system, it is important to also present the accompanying table of 
probabilities (absolute risk predictions), in order to allow the points score to be translated to a 
predicted risk. Decisions such as low, intermediate or high risk only based on a points total are 
uninformative unless it is clear how these are defined on the predicted absolute risk scale.  
A full worked example is provided in the supplementary material. For further details, including the 
mathematical formula associating the risk of outcome with each possible total point score for logistic 
and survival regression models, see Sullivan et al.21  
Advantages and limitations 
Points score systems are easy to understand following an initial explanation or demonstration, and 
therefore instructions on how to use it should be described alongside the points score system. 
Depending on the complexity of the model, and the number of included predictors, paper-based point 
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score systems can enable risks to be estimated quicker than inputting patient values directly into an 
online calculator, or published model. However, the predictions of risk (or survival) are only 
approximations of the actual predicted risk from the full model. This is because information on 
continuous predictor values is discarded by categorisation, and regression units are being rounded. 
Researchers must always check that the predictive performance of the simplified model based on a 
points score system is similar (and has same potential clinical impact) as the original full model. 
Application 
Table 3 illustrates a points score system for the primary biliary cirrhosis example. The table on the left 
assigns scores to categories of each predictor which have been scaled according to a 15-year increase 
in age (i.e. the regression coefficient for age multiplied by 15), while the table on the right provides 
probabilities of the outcome that correspond to the points total. For example, an individual aged 55 
years (0 points), with cirrhosis (3 points), albumin of 34.4g/dl (0 points), and central cholestasis (5 
points) has a points total of 8. This corresponds to a probability of death of 0.46 at one year and of 
0.90 at three years. These are very similar to the equivalent estimates of 0.44 and 0.89 for the risk of 
death at one and three years respectively directly obtained from the full model equation for this 
individual, suggesting that the simplification led to only small changes in risk predictions from the 
point scoring system for this individual. 
Table 3: Points score system for probability of death for new patients with primary biliary cirrhosis based on the model 
derived in Box 2.
Predictor Categories Points 
Age 
25-35 
35-45 
45-55 
55-65 
65-78 
-2 
-1 
-1 
0 
1 
Cirrhosis 
No 
Yes 
0 
3 
Albumin 
20.0-25.0 
25.0-30.0 
30.0-35.0 
35.0-40.0 
40.0-45.0 
45.0-50.0 
50.0-56.5 
2 
1 
0 
-1 
-2 
-3 
-4 
Central cholestasis 
No 
Yes 
0 
5 
Treatment 
Azathioprine 
Placebo 
0 
1 
 
 
Points 
total 
Probability of 
death at 1 year 
Probability of 
death at 3 years 
-6 0.008 0.029 
-5 0.011 0.040 
-4 0.014 0.054 
-3 0.020 0.073 
-2 0.027 0.098 
-1 0.036 0.131 
0 0.049 0.175 
1 0.067 0.231 
2 0.090 0.301 
3 0.121 0.387 
4 0.161 0.487 
5 0.213 0.598 
6 0.280 0.712 
7 0.361 0.818 
8 0.458 0.902 
9 0.566 0.958 
10 0.681 0.987 
11 0.790 0.997 
12 0.881 1.000 
Presentation using a graphical score chart 
Description 
Graphical score charts are highly-simplified, colour-coded versions of points score systems. As for the 
points score system, a graphical score chart is a presentation format for a prediction model with 
intended users of healthcare professionals and patients. It can be used either on screen, or as a print-
out. An example adopting this approach is the SCORE model for predicting cardiovascular disease.23 
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How to derive a graphical score chart 
First, the probability of the outcome must be calculated for each relevant combination of predictors 
using the formula in Box 1 based on the average value of the category or the group of individuals in 
that category in the development data. Probabilities can then be tabulated and colour coded based 
on clinically-important categories of risk. For example, those with higher risk predictions (near to 1) 
could be coded as red, and those with low risk predictions (near to 0) could be coded as yellow. 
Advantages and limitations 
Graphical score charts are easy to understand and the colour-coding can increase ease of use over 
points score systems.14 Additionally, decision guidelines can easily be coupled to the predictions e.g. 
dark red colour implies referral to intensive care for example. This enables stratification of patients to 
happen quickly. Choosing decision thresholds needs careful thought and evaluation; in particular, 
arbitrary cut-offs should be avoided.24  
This presentation will usually require some simplification of the model as it can only accommodate a 
limited number of predictors and requires continuous predictors to be presented as categories. There 
is also a loss of information regarding predicted risks as the results are typically presented as ranges 
of predicted risks rather than specific values. Each time point of interest requires its own graphical 
score chart too which is a further disadvantage. As for the points score system, the simplified model 
based on a score chart should be checked for its predictive performance (at each time-point of 
interest) compared to the full model. 
Application 
Table 4 demonstrates a graphical score chart for the primary biliary cirrhosis example. It was created 
using the point score system shown in Table 3. Risks of death of widths 0.1 might be considered 
clinically meaningful for example, up until 0.3, and were thus chosen as the four colour categories. 
According to this, risk of death at one year is 0.46 for a patient who is aged 55 years, with cirrhosis, 
central cholestasis, albumin of 34.4g/dl, and treated with azathioprine. This predicted risk is similar to 
the value of 0.44 estimated from the full model. 
Table 4: Graphical score chart for probability of death for new patients with primary biliary cirrhosis based on the model 
derived in Box 2 – restricted to patients receiving azathioprine treatment
Probability of death at 1 year 0.0-0.1 0.1-0.2 0.2-0.3 >0.3         
Azathioprine 
treatment 
No Central Cholestasis Central Cholestasis 
Albumin (g/dl) Albumin (g/dl) 
Age 
(yrs) 
Cirr. 
20 
to 
25 
25 
to 
30 
30 
to 
35 
35 
to 
40 
40 
to 
45 
45 
to 
50 
50+ 
20 
to 
25 
25 
to 
30 
30 
to 
35 
35 
to 
40 
40 
to 
45 
45 
to 
50 
50+ 
25 
to 
35 
No 0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.21 0.16 0.12 0.09 0.07 0.05 0.04 
Yes 0.12 0.09 0.07 0.05 0.04 0.03 0.02 0.46 0.36 0.28 0.21 0.16 0.12 0.09 
35 
to 
45 
No 0.07 0.05 0.04 0.03 0.02 0.01 0.01 0.28 0.21 0.16 0.12 0.09 0.07 0.05 
Yes 0.16 0.12 0.09 0.07 0.05 0.04 0.03 0.57 0.46 0.36 0.28 0.21 0.16 0.12 
45 
to 
55 
No 0.07 0.05 0.04 0.03 0.02 0.01 0.01 0.28 0.21 0.16 0.12 0.09 0.07 0.05 
Yes 0.16 0.12 0.09 0.07 0.05 0.04 0.03 0.57 0.46 0.36 0.28 0.21 0.16 0.12 
55 
to 
65 
No 0.09 0.07 0.05 0.04 0.03 0.02 0.01 0.36 0.28 0.21 0.16 0.12 0.09 0.07 
Yes 0.21 0.16 0.12 0.09 0.07 0.05 0.04 0.68 0.57 0.46 0.36 0.28 0.21 0.16 
Over 
65 
No 0.12 0.09 0.07 0.05 0.04 0.03 0.02 0.46 0.36 0.28 0.21 0.16 0.12 0.09 
Yes 0.28 0.21 0.16 0.12 0.09 0.07 0.05 0.79 0.68 0.57 0.46 0.36 0.28 0.21 
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Presentation using a nomogram 
Description 
Nomograms are another graphical presentation format for a clinical prediction model. As for the 
points score system, points are assigned based on the predictor values for a particular individual which 
are then equated to a risk of event, or survival probability.25 The intended user of a nomogram is 
healthcare professionals. They are best used as reference guides potentially on the wards or during a 
consultation. Like graphical score charts, nomograms can be coloured to aid interpretation.26  
How to derive a nomogram 
The steps to build a nomogram are as follows: 
1. For each predictor, calculate the maximum change in the developed model’s linear predictor 
by multiplying the predictors’ regression coefficient by the difference between the maximum 
and minimum value of the predictor in the dataset.  Order the predictors by their calculated 
maximum change. 
2. Assign up to 100 points for each predictor. First assign 100 points to the predictor with the 
largest maximum change as identified from step 1. Call this predictor A. Then provide a points 
score for the other predictors equal to 100 x (maximum change for the predictor / maximum 
change for predictor A). 
3. Calculate the minimum and maximum possible total points based on all possible combinations 
of predictors and project the points onto the probability scale by fitting a prediction model as 
in Box 1 with total points as the only predictor.  
Nomograms can be drawn using statistical software programmes such as R (via Harrell’s ‘rms’ package) 
and Stata (via ‘nomolog’ for logistic regression and ‘nomocox’ for Cox regression).27 28  
Advantages and limitations 
The main advantages of nomograms over the other presentation formats is that continuous predictors 
do not need to be categorised and multiple time points can be included in a single nomogram by 
including multiple probability scales based on the possible total points. Additionally, the relative 
importance of predictors can be judged by the length of the lines within the nomogram. Also, 
interaction and nonlinear terms can be well-handled.8 Complex models, for example those with time-
dependent predictors, can also be presented in this way.29 Nomograms can also easily be applied away 
from a computer, especially when a model includes only a small number of predictors. However, 
nomograms can appear relatively complex at first sight and they require an explanation as to how 
they should be used (as also highlighted in the TRIPOD Statement6). Additionally, they can be 
inaccurate depending on the size and resolution of the published figure, and the larger the number of 
predictors included in the model, the more challenging the nomogram is to interpret. Rounding of 
coefficients may also be required. 
Application  
Figure 1 shows the nomogram associated with the primary biliary cirrhosis example from Box 2. To 
determine the survival probability at a specified time point, the user identifies the points score 
associated with each predictor value by reading up from that predictor value to the points scale at the 
top. Once a score has been assigned to each predictor value, a total points score is calculated. 
Translation from total points to the probability of the outcome is then made by reading down to the 
associated probability of the outcome from the total points scale. Therefore, using Figure 1, we find 
that someone aged 55 years (24 points), with cirrhosis (42 points), albumin of 34.4g/dl (65 points), 
central cholestasis (62 points), and treated with azathioprine (0 points) has a total point score of 193. 
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This equates to a one year probability of death of 0.40 and a three year probability of 0.85, which are 
again very similar to the estimates of 0.44 and 0.89 obtained directly from the full regression formula. 
If the individual was not treated (32 points), but all other characteristics were unchanged, their total 
point score would be 171 which equates to a one and three year probability of death of 0.25 and 0.68 
respectively. 
Presentation within websites and applications (apps) 
Description 
Increasingly, prediction models are being made available via a website calculator or within an app for 
a tablet or smartphone device. These calculators and apps are generally interactive graphical user 
interfaces which provide individualised risk estimates from an underlying prediction model conditional 
on the users inputted predictor values. Often access is free, but sometimes a fee is charged.  
How to develop a website 
Websites are built using a building platform or content management system, and also require a 
domain name and web host. There are a variety of website building platforms, including specific tools 
that enable statistical software packages to run web apps for example Shiny for R and SWire for 
Stata.30 31 Websites and apps are available to both healthcare professionals and the general public. 
They can be used by interested individuals from anywhere in the world, or they can be designed for 
use in specific circumstances such as requiring log-in details from registered users, or via a National 
Health Service server to ensure that the information is delivered to the patient via a healthcare 
professional.  
Websites need to be explicit about the target user and target population, and any website or app 
should clearly state how to use the model. References to manuscripts describing the model 
development and subsequent validation (and potentially clinical impact evaluation) should also be 
provided. The website/app calculator should be checked to ensure that the predicted probability 
agrees with the predictions from the underlying regression model. For models with continuous 
predictors, entering values outside the range (of the development dataset) should also be restricted 
to avoid extrapolation, or at least provide a warning to the user.  
Advantages and limitations 
A major advantage is that the full model equation can be embedded behind the scenes, and thus no 
approximation is required, and any complexity is ‘hidden’ from the end user. Websites and apps can 
provide a user-friendly interface in front of complex statistical models which include large numbers of 
predictors, non-linear terms and interactions. Additionally, much of the data input could be 
automated – for example, in general practice the age and gender of the patient is likely to already be 
recorded in the medical centre’s computer system. Prediction models could be implemented within 
electronic health records to provide real-time feedback to clinicians although missing data and 
implausible values can be problematic. Digital applications easily enable switching between units for 
both laboratory results and anthropometrics such as height recorded in either metres or feet. 
As anyone can create a web calculator, there is currently no assurance that the underlying model is 
appropriate for use, has been developed adequately, or validated for the relevant populations 
accessing the website.32 Additionally, it is often difficult to know how the model has been translated 
into the graphical tool. The target user (e.g. healthcare professionals or patients) may also not be 
clear, and public access websites may lead to over-use or access by those for whom the model is not 
intended.  
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Clearly, access to the internet is also required. Data privacy and storage can additionally be a concern, 
particularly if a website is designed to collect as well as present data – this should be clearly signposted 
on the website/app. Also, accompanying graphical presentations such as colour-coded stick men, 
smiley faces or similar to demonstrate proportion of people predicted to have the outcome need to 
be carefully considered depending on the target user.33 34 Beside graphical presentations there are a 
large number of other metrics that can be used in risk communication derived from prediction models. 
Examples include the heart age metric recommended by the European Society of Cardiology.35 36 
Finally, the model may be updated over time to reflect changes in the underlying population 
characteristics. The web address may also change. In both cases the changes made may not have been 
tracked. Version control is therefore vital, as is reason for model update, both of which should be 
clearly sign-posted on the website. 
Application 
An example of a website is Your Heart Forecast tool from New Zealand.37 It provides a graphic design 
that compares a patient’s predicted cardiovascular disease risk against that of the healthy population 
of the same age. As risk can be hard to understand for patients, the model provides a graphical 
depiction of heart age and provides a future projection conditional on whether the individual does or 
does not modify their predictors. Other examples include GRACE (for acute coronary events)38, ASCVS 
Plus (for atherosclerotic cardiovascular disease) 39 and Predict (for breast cancer).10 Two examples of 
websites for primary biliary cirrhosis, although with different predictors to those in this manuscript’s 
running example, are UK-PBC40 and GLOBE.41 
Summary 
The format of presentation is an important consideration when a clinical prediction model is deemed 
suitable for use in clinical practice. In addition to providing the full equation (which is essential), there 
are many ways to present models to aid clinical use ranging from points score systems and 
nomograms, to websites and mobile apps. If a model is to be presented in a reduced format (e.g. 
predictors based on categorised values even though they were originally continuous in the full model) 
then this reduced model should be subject to the same validation process as the full model before it 
can be deemed suitable for clinical use. 
The best format is user- and environment-specific, with bedside tools for healthcare professionals 
requiring different options to patients at home on a computer or tablet. For this reason, means of 
presentation are best determined through stakeholder engagement, including healthcare 
professionals and patients. Empirical evidence is now required to determine whether certain formats 
promote better uptake, use or understanding. In due course, a similar guide will be required for 
models developed using advanced or alternative modelling techniques such as landmarking and 
machine learning. 
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Key Messages 
 Presentation format is an important issue for clinical prediction models deemed suitable for 
use, but receives relatively limited attention within the literature.  
 Clear presentation of a prediction model is fundamental to ensure other researchers can 
independently validate it, and that healthcare professionals and individuals can implement it 
within healthcare. 
 Presentation of the full model equation is essential. In addition, there are many ways to 
present prediction models for end-users ranging from points score systems and nomograms, 
to websites and mobile apps.  
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 The best presentation is user- and environment-specific and is best determined through 
stakeholder engagement, including patients 
 If presentation requires the generation of a simplified version of the full model, then the 
predictive performance of this simplified model should also be validated and compared to 
that of the full model. 
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Figure Legends 
Figure 1: Nomogram enabling predicted probabilities of death to be calculated at 1 and 3 years for 
new individuals with primary biliary cirrhosis. The underlying statistical model is that described in Box 
2. 
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